These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22353243)

  • 41. How We Think about Targeting RNA with Small Molecules.
    Costales MG; Childs-Disney JL; Haniff HS; Disney MD
    J Med Chem; 2020 Sep; 63(17):8880-8900. PubMed ID: 32212706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Online magnetic bead based dynamic protein affinity selection coupled to LC-MS for the screening of acetylcholine binding protein ligands.
    Pochet L; Heus F; Jonker N; Lingeman H; Smit AB; Niessen WM; Kool J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(20):1781-8. PubMed ID: 21565564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-based development of target-specific compound libraries.
    Orry AJ; Abagyan RA; Cavasotto CN
    Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategies for the design of RNA-binding small molecules.
    Aboul-ela F
    Future Med Chem; 2010 Jan; 2(1):93-119. PubMed ID: 21426048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of biomolecular interactions with complex-binding small molecules.
    Cai Z; Greene MI; Berezov A
    Methods; 2008 Sep; 46(1):39-46. PubMed ID: 18571508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes.
    Boer DR; Canals A; Coll M
    Dalton Trans; 2009 Jan; (3):399-414. PubMed ID: 19122895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ligand specificity in fragment-based drug design.
    Barelier S; Pons J; Gehring K; Lancelin JM; Krimm I
    J Med Chem; 2010 Jul; 53(14):5256-66. PubMed ID: 20575554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions.
    Geppert T; Bauer S; Hiss JA; Conrad E; Reutlinger M; Schneider P; Weisel M; Pfeiffer B; Altmann KH; Waibler Z; Schneider G
    Angew Chem Int Ed Engl; 2012 Jan; 51(1):258-61. PubMed ID: 22095772
    [No Abstract]   [Full Text] [Related]  

  • 49. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
    Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
    J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel strategy for three-dimensional fragment-based lead discovery.
    Yuan H; Lu T; Ran T; Liu H; Lu S; Tai W; Leng Y; Zhang W; Wang J; Chen Y
    J Chem Inf Model; 2011 Apr; 51(4):959-74. PubMed ID: 21438547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NMR fragment screening: Advantages and applications.
    Schade M
    IDrugs; 2006 Feb; 9(2):110-3. PubMed ID: 16523400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Practical aspects of NMR-based fragment discovery.
    Zartler ER; Mo H
    Curr Top Med Chem; 2007; 7(16):1592-9. PubMed ID: 17979770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A computational fragment-based de novo design protocol guided by ligand efficiency indices (LEI).
    Cortés-Cabrera Á; Gago F; Morreale A
    Methods Mol Biol; 2015; 1289():89-100. PubMed ID: 25709035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting RNA structures in diseases with small molecules.
    Shao Y; Zhang QC
    Essays Biochem; 2020 Dec; 64(6):955-966. PubMed ID: 33078198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery.
    Vanwetswinkel S; Heetebrij RJ; van Duynhoven J; Hollander JG; Filippov DV; Hajduk PJ; Siegal G
    Chem Biol; 2005 Feb; 12(2):207-16. PubMed ID: 15734648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Artificial synthetic receptors as regulators of protein activity.
    Dutt S; Wilch C; Schrader T
    Chem Commun (Camb); 2011 May; 47(19):5376-83. PubMed ID: 21394349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMR fragment screening: tackling protein-protein interaction targets.
    Schade M; Oschkinat H
    Curr Opin Drug Discov Devel; 2005 May; 8(3):365-73. PubMed ID: 15892252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the Druggability of Conserved RNA Regulatory Elements in the SARS-CoV-2 Genome.
    Sreeramulu S; Richter C; Berg H; Wirtz Martin MA; Ceylan B; Matzel T; Adam J; Altincekic N; Azzaoui K; Bains JK; Blommers MJJ; Ferner J; Fürtig B; Göbel M; Grün JT; Hengesbach M; Hohmann KF; Hymon D; Knezic B; Martins JN; Mertinkus KR; Niesteruk A; Peter SA; Pyper DJ; Qureshi NS; Scheffer U; Schlundt A; Schnieders R; Stirnal E; Sudakov A; Tröster A; Vögele J; Wacker A; Weigand JE; Wirmer-Bartoschek J; Wöhnert J; Schwalbe H
    Angew Chem Int Ed Engl; 2021 Aug; 60(35):19191-19200. PubMed ID: 34161644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The benefits of constructing leads from fragment hits.
    Foloppe N
    Future Med Chem; 2011 Jul; 3(9):1111-5. PubMed ID: 21806375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomimetic affinity ligands for immunoglobulins based on the multicomponent Ugi reaction.
    El Khoury G; Rowe LA; Lowe CR
    Methods Mol Biol; 2012; 800():57-74. PubMed ID: 21964782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.